The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer

被引:23
|
作者
Evangelista, Laura [1 ]
Basso, Umberto [2 ]
Maruzzo, Marco [2 ]
Novara, Giacomo [3 ]
机构
[1] IRCCS, Nucl Med & Mol Imaging Unit, Veneto Inst Oncol IOV, Via Gattamelata 64, I-35128 Padua, Italy
[2] IRCCS, Oncol Unit 1, Veneto Inst Oncol IOV, Padua, Italy
[3] Univ Padua, Urol Clin, Dept Surg Oncol & Gastroenterol, Padua, Italy
来源
EUROPEAN UROLOGY FOCUS | 2020年 / 6卷 / 01期
关键词
Computed tomography; Positron emission tomography; Prostate-specific membrane antigen; Renal cell carcinoma; CELL CARCINOMA; F-18-DCFPYL PET/CT; GA-68-PSMA PET/CT; F-18-FDG PET/CT; EXPRESSION; NEOVASCULATURE; UTILITY;
D O I
10.1016/j.euf.2018.08.004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Context: Preliminary results have demonstrated that prostate-specific membrane antigen (PSMA) is highly expressed on the cell surface of the microvasculature of several solid tumors, including renal cell carcinoma (RCC). Objective: To assess the role of PSMA positron emission tomography (PET)/computed tomography (CT) in RCC patients and to discuss its possible inclusion in the clinical management of these patients. Evidence acquisition: A systematic literature search was performed for studies on PET/CT in patients with RCC up to April 2018. MEDLINE databases, such as Pubmed, Web of Science, and Scopus were consulted using the following keywords: "Renal Cell Carcinoma" AND "PET/CT", "Renal Cancer" AND "PET/CT", "renal cancer" AND "PSMA PET/CT", and "renal cell carcinoma" AND "PSMA PET/CT". Evidence synthesis: Thirteen articles were retrieved from the available literature; the majority of them were relative to metastatic RCC (n = 11/13, 85%) and eight of them were clinical cases, thus providing low-quality data. No diagnostic benefit of PSMA PET/CT was found in the evaluation of primary tumors. PSMA PET/CT may be a useful imaging modality in whole-body staging and restaging of patients with RCC and in the assessment of lesions that remained unclear on conventional imaging. Furthermore, PSMA PET/CT may predict the response to anti-angiogenic-targeted therapies. Conclusions: The utility of PSMA-based PET imaging in the assessment of patients with RCC is encouraging. However, the available preliminary results will need to be addressed with larger prospective trials. Patient summary: In this mini-review, we evaluated the usefulness of an alternative imaging technique for patients with renal cell cancer. We found that this new imaging modality may indeed be useful. We conclude that the preliminary data should be assessed by larger studies. (C) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:146 / 150
页数:5
相关论文
共 50 条
  • [1] Microcosting Study of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Prostate Cancer
    Parkinson, Bonny
    Sharma, Rajan
    Jeet, Varinder
    Song, Rachel
    Hoyle, Martin
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 17 - 22
  • [2] Case - Prostate-specific antigen bounce: A pitfall in prostate-specific membrane antigen positron emission tomography/computed tomography interpretation
    Pedro, Victor Polins
    Sistani, Golmehr
    Rachinsky, Irina
    Zukotynski, Katherine
    Bauman, Glenn
    Liu, Wei
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2021, 15 (11): : E620 - E621
  • [3] Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Locally Advanced, Recurrent, and Metastatic Prostate Cancer
    Perera, Marlon
    Murphy, Declan
    Lawrentschuk, Nathan
    [J]. JAMA ONCOLOGY, 2018, 4 (05) : 748 - +
  • [4] Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
    Udovicich, Cristian
    Callahan, Jason
    Bressel, Mathias
    Ong, Wee Loon
    Perera, Marlon
    Tran, Ben
    Azad, Arun
    Haran, Shankar
    Moon, Daniel
    Chander, Sarat
    Shaw, Mark
    Eapen, Renu
    Goad, Jeremy
    Lawrentschuk, Nathan
    Murphy, Declan G.
    Hofman, Michael
    Siva, Shankar
    [J]. EUROPEAN UROLOGY OPEN SCIENCE, 2022, 44 : 60 - 68
  • [5] Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
    Asokendaran, Marcus Edward
    Meyrick, Danielle P.
    Skelly, Laura A.
    Lenzo, Nat P.
    Henderson, Andrew
    [J]. WORLD JOURNAL OF NUCLEAR MEDICINE, 2019, 18 (03) : 232 - 237
  • [6] A Case Series Study of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Early Evaluation of the Response to Systemic Therapy in Metastatic Renal Cancer
    Seront, Emmanuel
    Reichel, Cedric
    Lhommel, Renaud
    Tombal, Bertrand
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (05): : 1147 - 1149
  • [7] Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography
    Gupta, Manoj
    Choudhury, Partha Sarathi
    Rawal, Sudhir
    Singh, Amitabh
    [J]. WORLD JOURNAL OF NUCLEAR MEDICINE, 2021, 20 (01) : 113 - 116
  • [8] Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Radiomic Models in Prostate Cancer Prognostication
    Huynh, Linda My
    Swanson, Shea
    Cima, Sophia
    Haddadin, Eliana
    Baine, Michael
    [J]. CANCERS, 2024, 16 (10)
  • [9] Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer
    Haberkorn, Uwe
    Kopka, Klaus
    Hadaschik, Boris
    [J]. EUROPEAN UROLOGY, 2016, 69 (03) : 397 - 399
  • [10] Making the case for prostate-specific membrane antigen-targeted positron emission tomography/computed tomography in suspected prostate cancer
    Singh, Harmandeep
    [J]. INDIAN JOURNAL OF NUCLEAR MEDICINE, 2020, 35 (04): : 281 - 282